HER2-PET Imaging in HER2-low Breast Cancers

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Breast Cancer Metastatic

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Centre de recherche du CHUS, Sherbrooke, Quebec, Canada
Contact: Study coordinator (Michel Paquette, PhD) · michel.paquette@usherbrooke.ca · 819-346-1110
Contact: Study coordinator (Esteban Espinosa-Bentancourt) · Esteban.Espinosa-Bentancourt@USherbrooke.ca · 819-346-1110
Contact: Principal Investigator (Éric E Turcotte, MD, FRCPC)

Study leads

Éric E Turcotte, MD, FRCPC
Principal Investigator
Université de Sherbrooke

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer

Oligometastatic Breast Carcinoma · Breast Cancer · Metastatic Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Basking Ridge, United States · Middletown, United States

Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.

Breast Cancer

Abroad (travel likely)RecruitingPHASE2

La Jolla, United States

Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel

Triple Negative Breast Cancer Metastatic

Abroad (travel likely)RecruitingPHASE2

Novara, Italy · Bergamo, Italy

Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer

Breast Cancer Metastatic

Abroad (travel likely)RecruitingPHASE2

Seoul, South Korea